On the Couch
On the Couch with Dr Andreas Fouras (4DX): Lung Imaging, CTPA and the Billion-Dollar Opportunity
Jul 02, 2026
Marcus Today
In this episode of On the Couch, Henry Jennings speaks with Dr Andreas Fouras, Managing Director and CEO of 4DMedical (ASX: 4DX).
Many Marcus Today members will know 4DX from when it was a fraction of its current price. Henry has long been a fan of the company, which has developed XV Technology – a proprietary software platform enabling non-invasive, quantitative imaging and analysis of lung function.
They cover the opportunity in replacing CTPA scans, the Pro Medicus relationship, and what the next twelve months could look like for the business.
—
Marcus Today – Daily Market Insights
Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision-making without the noise.
If you'd like to go further:
Start a free 14-day trial of Marcus Today
http://bit.ly/mt-trial-podcast
Join Marcus Today
Use code MTPODCAST for 10% off
http://bit.ly/mt-join-podcast-offer
MT20 – Managed ETF Portfolio
A professionally managed portfolio run by Marcus Padley and the team, using ASX-listed ETFs with active market timing.
http://bit.ly/mt20-podcast
Principles – How We Think About Investing
A short video series on timing, behaviour, and decision-making. No stock tips.
http://bit.ly/mt-principles-podcast
—
Disclaimer
This podcast is general information only and does not consider your personal circumstances. It is not personal financial advice.
On the Couch with Dr Andreas Fouras (4DX): Lung Imaging, CTPA and the Billion-Dollar Opportunity
38:59
On the Couch with Igor Pejic: New Rules for Investing in the Tech Age
39:03
.png)
On the Couch with Jonathon Higgins (UCP): Neoclouds, Electrification and the ASX Opportunity
36:33
On the Couch with Alex Pollak (Loftus Peak): AI, Disruption and Where the Money Is Going
43:36
On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead
38:23
On the Couch with Jon Pilcher (Neuren): DAYBUE, Europe and What Comes Next
34:50
On the Couch with Nick Griffin (Munro Partners): Markets, AI and Global Tech Themes
47:02
Why the Next Six Months Could Get Tough for Small Caps: On the Couch with Chris Stott
36:51
On the Couch with Coby Hanoch (Weebit Nano): The Memory Boom Behind AI
37:04
On the Couch With Richard Morrow (Lowell Resources): Talking Gold and Gold Stocks
39:12
On the Couch with Gary Norden: Inside a 35-Year Trading Career
48:52
On the Couch with Andrew Wielandt (DP Wealth): The ETF Whisperer's 2026 Playbook
31:29
On the Couch with Scott Kirkland (ASX: EMV): The Future of Stroke Diagnosis Starts Here
23:57
.png)
On the Couch with Nathan Smith (Neuroscientific): Inside the StemSmart Strategy for Crohn's
35:44
On the Couch with Louise Bedford: Trading Discipline in a Noisy Market
36:43
On the Couch with Jonathon Higgins (Unified Capital Partners): Stock Picks, Sector Shifts and What's Ahead
37:45
On the Couch with Armina Rosenberg (Minotaur Capital): How AI Is Rewriting the Rules of Investing
33:09
On the Couch with Adam Dawes (Shaw and Partners): Top Stocks and Themes for 2026
37:24
On the Couch with Dr Francis Wedin (ASX: VUL): Inside the Lionheart Funding Deal
27:36
On the Couch with Jon Pilcher (Neuren): The Real Growth Story Is Just Starting
30:46
.png)
On the Couch with Robert Bubalovski (Trade View): Beating the Market with Algos and AI
46:43
On the Couch with Louise Bedford: Smart Trading in Tough Conditions
38:50
.png)
On the Couch with Jonathon Higgins and James Bisinella (UCP): Talking Top Recommendations
38:10
.png)
On the Couch with Dr Mark Bennett (ASX: FAL): Why Falcon Is Flying
18:24
.png)
On the Couch with Jim Corbett (ASX: AVH): What's Next for AVITA Medical
39:55